正常前列腺18F-FDG PET/CT显像的FDG摄取研究

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (510 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To determine the FDG uptake of the normal prostate gland with 18F-FDG PET/CT imaging and its influence factors. Methods The normal prostates in 83 men detected by 18F-FDG PET/CT imaging in Beijing Hospital from November 2014 to January 2016 were analyzed retrospectively, aged 20-91, average of (60±18) years. Their PET/CT imaging characteristics were analyzed. ROI technology was used for getting the SUVmax and SUVavg, and the diameters of prostate gland were detected in the maximum shear plane. Correlations among the SUV, prostate size and age were analyzed by Pearson correlation analysis with SPSS 17.0. Results The average of SUV maximum and mean was (2.3±0.4) and (1.6±0.3) respectively. The average of normal prostate gland size was (4.4±0.7) cm. There was positive correlation between prostate size and age (r=0.365, P < 0.05), but there was no statistically significant relationship between the SUV (SUVmax and SUVavg) and the size of normal prostate gland (P > 0.05), the SUV (SUVmax and SUVavg) of the prostate gland was not significantly related with age also (P > 0.05). Conclusion The prostate gland size get larger as age increased, but the age and the size are not influence the FDG uptake of the prostate gland with 18F-FDG PET/CT imaging.

Key words： Prostete gland Tomography Emission-computed Deoxyglucose

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Wen ZHANG Jianfei LIU Xiuqin

Cite this article:

CHEN Wen ZHANG Jianfei LIU Xiuqin. The FDG uptake of the normal prostate gland with 18F-FDG PET/CT imaging[J]. 中国医药导报, 2017, 14(16): 102-105.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I16/102

[1] Grant K，Lindenberg ML，Shebel H，et al. Functional and molecular imaging of localized and recurrent prostate cancer [J]. Eur J Nucl Med Mol Imaging，2013，40（1）：48-59.
[2] Jadvar H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT：utility and limitations [J]. Eur J Nucl Med Mol Imaging，2013，40（Suppl 1）：5-10.
[3] Yang ZY，Hu SL，Cheng JY，et al. Prevalence and risk of cancer of incidental uptake in prostate identified by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography [J]. Clin Imaging，2014，38（4）：470-474.
[4] Vaz CV，Marques R，Alves MG，et al. Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by modulating the expression of GLUT1，GLUT3，PFK，LDH and MCT4 genes [J]. J Cancer Res Clin Oncol，2016，142（1）：5-16.
[5] Macheda ML，Rogers S，Best JD. Molecular and cellular regulation of glucose transporter（GLUT）proteins in cancer [J]. J Cell Physiol，2005，202（3）：654-662.
[6] Stewardt GD，Gray K，Pennington CJ，et al. Analysis of hypoxia-associated gene expression in prostate cancer：lysyl oxidase and glucose transporter-1 expression correlate with Gleason score [J]. Oncol Rep，2008，20（6）：1561-1567.
[7] Takahashi N，Inoue T，Lee J，et al. The roles of PET and PET/CT in the diagnosis and management of prostate cancer [J]. Oncology，2007，72（3-4）：226-233.
[8] Von MD，Backhaus B，Muller SC，et al. Technical limits of PET/CT with 18FDG in prostate cancer [J]. Aktuelle Urol，2006，37（3）：218-221.
[9] Wilkinson C，Chowdhury F，Scarsbrook A，et al. BCG-induced granulomatous prostatitis-an incidental finding on FDG PET-CT [J]. Clin Imaging，2012，36（4）：413-415.
[10] Minamimoto R，Uemura H，Sano，et al. The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level [J]. Ann Nucl Med， 2011，25（1）：21-27.
[11] Yu CY，Desai B，Ji LY，et al. Comparative performance of PET tracers in biochemical recurrence of prostate cancer：a critical analysis of literature [J]. Am J Nucl Med Mol Imaging，2014，4（6）：580-601.
[12] 林美福，周硕，陈文新，等.18F-FDG 18F-FECH双示踪剂PET/CT在前列腺癌诊疗中的应用[J].福建医科大学学报，2012，46（5）：366-369.
[13] Patel AR，Jones JS，Rabets J，et al. Parasagittal biopsies add minimal information in repeat saturation prostate biopsy [J]. Urology，2004，63（1）：87-89.
[14] Schoder H，Herrmann K，Gonen M，et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for detection of disease in patients with prostatespecific antigen relapse after radical prostatectomy [J]. Clin Cancer Res，2005，11（13）：4761-4769.
[15] Meirelles GS，Schoder H，Ravizzini GC，et al. Prognostic value of baseline fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer [J]. Clin Cancer Res，2010，16（24）：6093-6099.
[16] Jadvar H，Desai B，Ji L，et al. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer [J]. Clin Nucl Med，2012，37（7）：637-643.
[17] ■ztürk H，Karapolat I. 18F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer [J]. Oncol Lett，2016，11（1）：316-322.
[18] Wang Y，Chiu R，Rosenberg J，et al. Standardized uptake value atlas： characterization of physiological 2-deoxy-2-[18F]fluoro-D-glucose uptake in normal tissues [J]. Mol Imaging Biol，2007，9（2）：83–90.
[19] Jadvar H，Ye W，Groshen S，et al. [F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland [J]. Ann Nucl Med，2008，22（9）：787-793.
[20] Turlakow A，Larson SM，Coakley F，et al. Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose： comparison of filtered back projection and iterative reconstruction with segmented attenuation correction [J]. Q J Nucl Med，2001，45（3）：235-244.